First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
Amgen
University of Maryland, Baltimore
Memorial Sloan Kettering Cancer Center
University of California, Davis
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
Northwestern University
National Cancer Institute (NCI)
AstraZeneca
GlaxoSmithKline
SWOG Cancer Research Network
Barbara Ann Karmanos Cancer Institute